Efungumab

Summary

Efungumab (CHEMBL1743009) is a phase-3 clinical-stage antibody; indicated across 2 conditions including cryptococcal meningitis and breast carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743009
Name	Efungumab
Type	Antibody
Max phase	3

Also known as: Efungumab, HSP-90MAB, HSP90MAB, MYC-123, MYC-123A, MYC-123A MYC-123B MYC-124 HSP90MAB, MYC-123B, MYC-124, MYC123, MYC123A, MYC123B, MYC124

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Cryptococcal meningitis	2	MONDO:0005723	EFO:0007228
breast carcinoma	1	MONDO:0004989	EFO:0000305

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00217815	PHASE1/PHASE2	COMPLETED	Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
NCT00324025	PHASE2	TERMINATED	Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
NCT00847678	PHASE2	TERMINATED	Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).